Adicet Bio is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off ...

MAIA Biotechnology (MAIA) announced updated data from its THIO-101 pivotal Phase 2 clinical trial evaluating its lead clinical candidate, THIO, sequenced with Regeneron’s (REGN) immune ...

The BioXplorer 100 from H.E.L is a multi-bioreactor system that has been specifically developed for the optimization of aerobic fermentations. Having a working volume as low as 50 mL, the ...

Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced that management will ...

Nanoscope Therapeutics Inc., a biotechnology company committed to restoring vision in blind patients in real-world settings ...

Browse 100+ biotech logo stock videos and clips available to use in your projects, or start a new search to explore more stock footage and b-roll video clips. DNA Strand Science molecule design icon ...

However, some life sciences firms such as Danaher (DHR.N), opens new tab have indicated smaller biotech clients are still cautious with their investments despite the rate cuts. Sales at Bio-Techne ...

They show that he plans to divest stock holdings, including stakes in biotech firms CRISPR Therapeutics AG and Dragonfly Therapeutics. He’s also stepping down from roles at his law firm and at ...

Olive oil bioactives, including MUFAs, polyphenols, and triterpenoids, modulate gene expression linked to insulin sensitivity ...

The chairman of the Illinois Soybean Association (ISA) says a newfound use for soybean oil could someday spur major demand.

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins Some states have laws and ethical rules regarding solicitation and ...

Story Feb. 11 - Third Harmonic Bio: The biotech announced it will lay off half of its workforce as it prepares to take its chronic spontaneous urticaria candidate into phase 2. Story Feb. 10 - Q32 ...